Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Clinical Trials Arena on MSN

MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Fierce Biotech

Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Fierce Pharma

Gilead hails phase 3 victory for single-tablet combo of bictegravir and lenacapavir, preps filings

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...

Merck HIV therapy matches Gilead’s Biktarvy in late-stage trial

Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...

Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Managed Healthcare Executive

Gilead’s Single-Tablet HIV Regimen Meets Primary Endpoints

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
BioSpace

Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...